A Phase 1 First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Malignant Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS-986406 (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Brain metastases; Carcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Bristol-Myers Squibb

26 Sep 2024 Status changed from active, no longer recruiting to completed.
03 Jul 2024 Planned End Date changed from 15 Jul 2024 to 9 Aug 2024.
03 Jul 2024 Planned primary completion date changed from 15 Jul 2024 to 9 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com